This page contains exclusive content for the member of the following sections: TTS. Log in to view.
Clinical Immunosuppression New Agents
24.8 - Benefit-Risk Profile of the Belatacept LI Regimen at 2 Years in EBV(+) Kidney Transplant Recipients
Presenter: Flavio, Vincenti, San Francisco, United States Authors: Vincenti F., Grinyo J., Larsen C., Pestana J., Vanrenterghem Y., Duan T., Agarwal M., Charpentier B.
Important
Disclaimer
By viewing the material on this site you understand and
accept that:
The opinions and statements expressed on this site reflect the
views of the author or authors and do not necessarily reflect those of
The Transplantation Society and/or its Sections.
The hosting of material on The Transplantation Society site does
not signify endorsement of this material by The Transplantation Society
and/or its Sections.
The material is solely for educational purposes for qualified
health care professionals.
The Transplantation Society and/or its Sections are not liable for
any decision made or action taken based on the information contained in
the material on this site.
The information cannot be used as a substitute for professional
care.
The information does not represent a standard of care.
No physician-patient relationship is being established.